MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
Immutep Limited Total Shareholders Equity 2011-2026 | IMMP
Annual Total Shareholders Equity Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 33.3 M | 24.4 M | 33.5 M | 26.5 M | 35.3 M | - | - | - | - | - |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.3 M | 24.4 M | 30.6 M |
Quarterly Total Shareholders Equity Immutep Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 73.3 M | - | - | - | 33.3 M | - | - | - | 24.4 M | - | - | - | 33.5 M | - | - | - | 26.5 M | - | - | - | 35.3 M | - | - | - | 24.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in AUD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.3 M | 24.4 M | 35.9 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M |  USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 217.23 | -0.38 % | $ 5 B |  Danmark |
 |
Aurinia Pharmaceuticals
AUPH
|
581 M | $ 13.92 | -4.4 % | $ 1.87 B |  Canada |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.22 | -0.05 % | $ 898 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.65 | 0.61 % | $ 193 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
13.5 M | $ 0.66 | 9.41 % | $ 7.56 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
CytomX Therapeutics
CTMX
|
99 M | $ 4.26 | -4.48 % | $ 588 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.41 | 0.36 % | $ 360 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Exelixis
EXEL
|
2.16 B | $ 41.18 | -0.56 % | $ 11.2 B | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.63 | - | $ 16.5 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Fulcrum Therapeutics
FULC
|
349 M | $ 6.71 | -2.61 % | $ 425 K | USA |
 |
Genmab A/S
GMAB
|
14 B | $ 25.65 | -0.14 % | $ 16.3 B | Danmark |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
Grifols, S.A.
GRFS
|
6.72 B | $ 7.7 | 0.07 % | $ 6.83 B |  Spain |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Halozyme Therapeutics
HALO
|
48.8 M | $ 62.24 | -0.99 % | $ 7.46 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.25 | -3.96 % | $ 814 M | Canada |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Immatics N.V.
IMTX
|
87.4 M | $ 9.35 | -1.74 % | $ 588 M | Germany |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | USA |